ESTRO 2025 - Abstract Book

S869

Clinical - Gynaecology

ESTRO 2025

Conclusion: The presented results confirm the excellent oncological outcomes in this cohort of latin american patients, identifying as prognostic variables overall treatment time and chemotherapy cycles.

Keywords: cervical cancer, overall survival, cohort

References: 1. Pötter R, Chargari C, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021;22(4):538-547. 2. Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, Petric P, Šegedin B, Jurgenliemk-Schulz IM, Nomden C, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol. 2016;120(3):428-433. doi:10.1016/j.radonc.2016.03.011.

4030

Digital Poster Definitive Radiotherapy for Vulvovaginal Squamous Cell Carcinoma: Clinical Outcomes from a Single-Center Retrospective Study Wajana Thaweerat, Pittaya Dankulchai, Tissana Prasartseree, Wiwatchai Sittiwong, Yaowalak Chansilpa Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Purpose/Objective: The study aimed to retrospectively report the clinical outcomes of patients with vulvovaginal squamous cell carcinoma who were treated with definitive radiotherapy at a single center. Material/Methods: Patients with histologically confirmed vulvovaginal squamous cell carcinoma and no history of other malignancies, who received definitive radiotherapy between 2015 and 2022 at a single institution, were included. A retrospective chart review was conducted to retrieve patient characteristics, treatment regimens, toxicities, and oncologic outcomes. Acute and late toxicities were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Results: Nine patients with vaginal cancer and thirteen patients with vulvar cancer were treated with definitive radiotherapy. Patient characteristics and treatment data are presented in Table 1. Thirteen patients (59%) were treated with external beam radiotherapy, while nine patients (41%) received external beam radiotherapy with a brachytherapy boost. Eighteen patients (82%) received concurrent chemotherapy, and one patient (5%) received adjuvant chemotherapy. The median follow-up time was 30.5 months. The most common grade 3 acute toxicity was skin related, affecting 45% of all patients, while grade 3 hematologic toxicity occurred in 22% of patients who received concurrent chemotherapy. No grade 3 gastrointestinal or genitourinary toxicities were observed. Late skin, gastrointestinal, genitourinary, and vaginal toxicities are shown in Figure 1, with no grade 3 late toxicities detected. Twenty-one patients (95%) achieved a complete response, while one patient (5%) had a partial response. Four patients (18%) experienced local progression, with a median time-to-progression of 9 months. Three patients developed distant metastasis after treatment, with two patients still under local control.